This is further supported by its association with higher pathological stage, elevated alpha-fetoprotein (AFP) levels, and poor prognosis, indicating FLAD1’s potential as an HCC biomarker and could be targeted for therapeutic intervention. The gene discussed is AFP; the disease is hepatocellular carcinoma.